These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

299 related items for PubMed ID: 21976531

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells.
    Kim A, Park S, Lee JE, Jang WS, Lee SJ, Kang HJ, Lee SS.
    Leuk Res; 2012 Jul; 36(7):912-20. PubMed ID: 22560334
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. NVP-BEZ235 as a new therapeutic option for sarcomas.
    Manara MC, Nicoletti G, Zambelli D, Ventura S, Guerzoni C, Landuzzi L, Lollini PL, Maira SM, García-Echeverría C, Mercuri M, Picci P, Scotlandi K.
    Clin Cancer Res; 2010 Jan 15; 16(2):530-40. PubMed ID: 20068094
    [Abstract] [Full Text] [Related]

  • 25. Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy.
    Chang Z, Shi G, Jin J, Guo H, Guo X, Luo F, Song Y, Jia X.
    Int J Mol Med; 2013 Jun 15; 31(6):1449-56. PubMed ID: 23588698
    [Abstract] [Full Text] [Related]

  • 26. Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of mTOR.
    Chen SM, Liu JL, Wang X, Liang C, Ding J, Meng LH.
    Biochem Pharmacol; 2012 May 01; 83(9):1183-94. PubMed ID: 22305748
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Hispidulin, a small flavonoid molecule, suppresses the angiogenesis and growth of human pancreatic cancer by targeting vascular endothelial growth factor receptor 2-mediated PI3K/Akt/mTOR signaling pathway.
    He L, Wu Y, Lin L, Wang J, Wu Y, Chen Y, Yi Z, Liu M, Pang X.
    Cancer Sci; 2011 Jan 01; 102(1):219-25. PubMed ID: 21087351
    [Abstract] [Full Text] [Related]

  • 29. Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer.
    Zhu Y, Tian T, Zou J, Wang Q, Li Z, Li Y, Liu X, Dong B, Li N, Gao J, Shen L.
    BMC Cancer; 2015 Nov 11; 15():894. PubMed ID: 26560145
    [Abstract] [Full Text] [Related]

  • 30. Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging.
    Schnell CR, Stauffer F, Allegrini PR, O'Reilly T, McSheehy PM, Dartois C, Stumm M, Cozens R, Littlewood-Evans A, García-Echeverría C, Maira SM.
    Cancer Res; 2008 Aug 15; 68(16):6598-607. PubMed ID: 18701483
    [Abstract] [Full Text] [Related]

  • 31. Human urine extract CDA-2 induces apoptosis of myelodysplastic syndrome-derived MUTZ-1 cells through the PI3K/Akt signaling pathway in a caspase-3-dependent manner.
    Huang J, Yang M, Liu H, Jin J.
    Acta Pharmacol Sin; 2008 Aug 15; 29(8):951-64. PubMed ID: 18664328
    [Abstract] [Full Text] [Related]

  • 32. The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma.
    Oishi T, Itamochi H, Kudoh A, Nonaka M, Kato M, Nishimura M, Oumi N, Sato S, Naniwa J, Sato S, Shimada M, Kigawa J, Harada T.
    Oncol Rep; 2014 Aug 15; 32(2):553-8. PubMed ID: 24927217
    [Abstract] [Full Text] [Related]

  • 33. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
    Liu H, Scholz C, Zang C, Schefe JH, Habbel P, Regierer AC, Schulz CO, Possinger K, Eucker J.
    Anticancer Res; 2012 May 15; 32(5):1627-37. PubMed ID: 22593441
    [Abstract] [Full Text] [Related]

  • 34. Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells.
    Sunayama J, Matsuda K, Sato A, Tachibana K, Suzuki K, Narita Y, Shibui S, Sakurada K, Kayama T, Tomiyama A, Kitanaka C.
    Stem Cells; 2010 Nov 15; 28(11):1930-9. PubMed ID: 20857497
    [Abstract] [Full Text] [Related]

  • 35. Identification of 2-oxatriazines as highly potent pan-PI3K/mTOR dual inhibitors.
    Dehnhardt CM, Venkatesan AM, Chen Z, Delos-Santos E, Ayral-Kaloustian S, Brooijmans N, Yu K, Hollander I, Feldberg L, Lucas J, Mallon R.
    Bioorg Med Chem Lett; 2011 Aug 15; 21(16):4773-8. PubMed ID: 21763134
    [Abstract] [Full Text] [Related]

  • 36. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
    Mohan S, Vander Broek R, Shah S, Eytan DF, Pierce ML, Carlson SG, Coupar JF, Zhang J, Cheng H, Chen Z, Van Waes C.
    Clin Cancer Res; 2015 Sep 01; 21(17):3946-56. PubMed ID: 25977343
    [Abstract] [Full Text] [Related]

  • 37. The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.
    Bean JR, Hosford SR, Symonds LK, Owens P, Dillon LM, Yang W, Shee K, Schwartz GN, Marotti JD, Muller KE, Rosenkranz KM, Barth RJ, Chen VS, Agarwal VR, Miller TW.
    Breast Cancer Res Treat; 2015 Jan 01; 149(1):69-79. PubMed ID: 25491778
    [Abstract] [Full Text] [Related]

  • 38. Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice.
    Dai C, Zhang B, Liu X, Ma S, Yang Y, Yao Y, Feng M, Bao X, Li G, Wang J, Guo K, Ma W, Xing B, Lian W, Xiao J, Cai F, Zhang H, Wang R.
    Endocrinology; 2013 Mar 01; 154(3):1247-59. PubMed ID: 23384836
    [Abstract] [Full Text] [Related]

  • 39. Centchroman inhibits proliferation of head and neck cancer cells through the modulation of PI3K/mTOR pathway.
    Srivastava VK, Gara RK, Bhatt ML, Sahu DP, Mishra DP.
    Biochem Biophys Res Commun; 2011 Jan 07; 404(1):40-5. PubMed ID: 21094138
    [Abstract] [Full Text] [Related]

  • 40. Dual-Blocking of PI3K and mTOR Improves Chemotherapeutic Effects on SW620 Human Colorectal Cancer Stem Cells by Inducing Differentiation.
    Kim MJ, Koo JE, Han GY, Kim B, Lee YS, Ahn C, Kim CW.
    J Korean Med Sci; 2016 Mar 07; 31(3):360-70. PubMed ID: 26955235
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.